Abbott Laboratories GmbH
Records under this name other than patents Abbott Laboratories GmbH holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Abbott Laboratories GmbH
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,278,603 | Enzyme Compositions with Reduced Viral and Microbial Contamination Formerly held In force · High confidence | In force | High confidence | |
| US 6,300,336 | Method of treating or inhibiting functional disturbances or illnesses of the lower intestinal tracts, particularly abdominal visceral pain which accompanies them Term ended Term ended Mar 15, 2020 · From the USPTO record | Term ended | Term ended Mar 15, 2020 | From the USPTO record |
| US 6,069,147 | Thermogenesis stimulating drugs Formerly held Term ended Term ended Apr 6, 2019 · From the USPTO record | Term ended | Term ended Apr 6, 2019 | From the USPTO record |
| US 8,114,906 | Essential Fatty Acids in the Treatment And/Or Inhibition of Depression in Patients with Coronary Heart or Artery Disease Lapsed on the fee record Ended Feb 14, 2016 · High confidence | Lapsed on the fee record | Ended Feb 14, 2016 | High confidence |
| US 7,309,706 | Method for the Treatment of Diseases Requiring Inhibition or a Reduction in the Activity of PH Value-Regulating Bicarbonate Transporter Proteins Lapsed on the fee record Ended Dec 18, 2015 · High confidence | Lapsed on the fee record | Ended Dec 18, 2015 | High confidence |
| US 7,087,620 | Liquid Pharmaceutical Formulations Containing 3,7-Diazabicyclo[3,3,1] Nonane Compounds and Methods of Treatment Relating to Anti-Arrhythmic Events Lapsed on the fee record Ended Aug 8, 2014 · High confidence | Lapsed on the fee record | Ended Aug 8, 2014 | High confidence |
| US 7,041,303 | Use of Moxonidine for Postmyocardial Infarction Treatment Lapsed on the fee record Ended May 9, 2014 · High confidence | Lapsed on the fee record | Ended May 9, 2014 | High confidence |
| US 5,183,821 | Method for treating leukemias using N-(2-dimethylaminoethyl)-3-amino-1,8-naphthalimide for treating leukemias and solid tumors Formerly held Term ended Term ended no later than Feb 2, 2013 · Low confidence | Term ended | Term ended no later than Feb 2, 2013 | Low confidence |
| US 5,324,732 | Crystalline fumaric acid salts of 9,9-alkylene-3,7-diazabicyclononane compounds and pharmaceutical compositions containing them Term ended Term ended no later than Jun 28, 2014 · Low confidence | Term ended | Term ended no later than Jun 28, 2014 | Low confidence |
| US 5,712,283 | Method of inhibiting hyperglycemia and pharmaceutical composition for use therein Term ended Term ended no later than Jan 27, 2018 · Low confidence | Term ended | Term ended no later than Jan 27, 2018 | Low confidence |